猪口孝一
International Journal of Recent Scientific Research.2016 7: 9729-9733.
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. Oncol Rep.2016: 36:2976-2982.
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunol Res. 2016 4:779-88.
The Therapeutic Outcomes of Mechanical Ventilation in Hematological Malignancy Patients with Respiratory Failure. Intern Med. 2016 55:1537-45
Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations. Haematologica.
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.Am J Hematol.2015;90:282-7.
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase. J Clin Exp Hematop.2014 54:197-204.
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.
1990年 日本医科大学同窓会医学研究助成金・受賞
1991年 内藤記念科学奨励金・受賞
1992年 上原記念生命科学財団研究奨励金・受賞
1993年 日本医科大学医学会奨学賞・受賞
1996年 東京都医師会医学研究奨励賞・受賞
2000年・2001年 高橋産業経済研究財団研究助成金・受賞